BRPI0413373A - compostos compreendendo lpa - Google Patents

compostos compreendendo lpa

Info

Publication number
BRPI0413373A
BRPI0413373A BRPI0413373-0A BRPI0413373A BRPI0413373A BR PI0413373 A BRPI0413373 A BR PI0413373A BR PI0413373 A BRPI0413373 A BR PI0413373A BR PI0413373 A BRPI0413373 A BR PI0413373A
Authority
BR
Brazil
Prior art keywords
compounds
amino acid
fgfr
acid sequences
lpa
Prior art date
Application number
BRPI0413373-0A
Other languages
English (en)
Inventor
Morten Albrechtsen
Elisabeth Bock
Vladimir Berezin
Arne Holm
Original Assignee
Enkam Pharmaceuticals As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enkam Pharmaceuticals As filed Critical Enkam Pharmaceuticals As
Publication of BRPI0413373A publication Critical patent/BRPI0413373A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)

Abstract

"COMPOSTOS COMPREENDENDO LPA". A presente invenção se refere a novos compostos de peptídeo capazes de se ligarem ao receptor de fator de crescimento de fibroblasto (FGFR) , os referidos compostos compreendendo duas seqüências de aminoácido individuais, onde pelo menos uma das duas seqüências de aminoácido é capaz de se ligar ao FGFR. A invenção divulga as seqüências de aminoácido dos compostos, e as composições farmacêuticas características os compreendendo. A invenção também se refere ao uso dos compostos e composições farmacêuticas os compreendendo, para o tratamento ou prevenção de diferentes condições patológicas, onde FGFR desempenha uma função na patologia e/ou recuperação da doença. os novos compostos de peptídeo da invenção são obteníveis pelo método de montagem de apresentação de ligando (LPA).
BRPI0413373-0A 2003-08-07 2004-08-06 compostos compreendendo lpa BRPI0413373A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301141 2003-08-07
DKPA200400814 2004-05-25
PCT/DK2004/000527 WO2005014623A2 (en) 2003-08-07 2004-08-06 Compounds comprising lpa

Publications (1)

Publication Number Publication Date
BRPI0413373A true BRPI0413373A (pt) 2006-10-17

Family

ID=34137357

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413373-0A BRPI0413373A (pt) 2003-08-07 2004-08-06 compostos compreendendo lpa

Country Status (11)

Country Link
US (1) US20090105149A1 (pt)
EP (1) EP1660539B1 (pt)
JP (1) JP2007526898A (pt)
AT (1) ATE469921T1 (pt)
AU (1) AU2004263203A1 (pt)
BR (1) BRPI0413373A (pt)
CA (1) CA2534355A1 (pt)
DE (1) DE602004027508D1 (pt)
IL (1) IL173532A0 (pt)
MX (1) MXPA06001501A (pt)
WO (1) WO2005014623A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE552273T1 (de) * 2001-08-17 2012-04-15 Enkam Pharmaceuticals As Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
EP1678200B1 (en) * 2003-09-30 2012-05-02 Enkam Pharmaceuticals A/S A method of modulating cell survival, differentiation and/or synaptic plasticity
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
AU2006315562C1 (en) * 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
US7635790B2 (en) 2006-02-14 2009-12-22 Basf Se Method for producing ethylene amines and ethanol amines by the hydrogenating amination of monoethylene glycol and ammonia in the presence of a catalyst
WO2007093177A2 (en) 2006-02-14 2007-08-23 Vladimir Berezin Metallothionein-derived peptide fragments
WO2007093514A1 (de) 2006-02-14 2007-08-23 Basf Se Verfahren zur herstellung von ethylenaminen und ethanolaminen aus monoethylenglykol (meg)
US20100172886A1 (en) * 2006-11-28 2010-07-08 University Of Southern California Method for Promoting Wound Healing
WO2009068042A2 (en) * 2007-11-28 2009-06-04 Enkam Pharmaceuticals A/S Novel peptides derived from ncam (fgls)
WO2009100724A1 (en) * 2008-02-11 2009-08-20 Kobenhavns Universitet Novel peptide derived from ncam (bcl)
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
WO2013184824A1 (en) * 2012-06-05 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
EP3441109A1 (en) 2013-05-30 2019-02-13 Graham H. Creasey Flexible dermal patch for a topical nerve stimulator system
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
WO2019094365A1 (en) 2017-11-07 2019-05-16 Neurostim Oab, Inc. Non-invasive nerve activator with adaptive circuit
CA3144957A1 (en) 2019-06-26 2020-12-30 Neurostim Technologies Llc Non-invasive nerve activator with adaptive circuit
WO2021126921A1 (en) 2019-12-16 2021-06-24 Neurostim Solutions, Llc Non-invasive nerve activator with boosted charge delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629291A (en) * 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US5840689A (en) * 1993-10-29 1998-11-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for stimulating the regrowth of neurons
US5693488A (en) * 1994-05-12 1997-12-02 The Rockefeller University Transmembrane tyrosine phosphatase, nucleic acids encoding the same, and methods of use thereof
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US6313265B1 (en) * 1995-07-24 2001-11-06 The Scripps Research Institute Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
DE69912827T2 (de) * 1998-09-29 2004-10-21 Loke Diagnostics Aps Aarhus "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US7167819B1 (en) * 1999-05-26 2007-01-23 Chiron Corporation Method of determining the three-dimensional shape of a macromolecule
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
AU7078200A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
AU2002256545A1 (en) * 2000-12-12 2002-06-24 Enkam Pharmaceuticals A/S Survical promoting ncam binding and ncam ligand biding compounds
ATE552273T1 (de) * 2001-08-17 2012-04-15 Enkam Pharmaceuticals As Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
EP1436318A2 (en) * 2001-09-05 2004-07-14 Enkam Pharmaceuticals A/S Ncam binding compounds
JP2007524566A (ja) * 2002-12-20 2007-08-30 エンカム ファーマシューティカルズ アクティーゼルスカブ レセプターとリガンドの間の相互作用の調節の方法

Also Published As

Publication number Publication date
MXPA06001501A (es) 2006-09-04
CA2534355A1 (en) 2005-02-17
JP2007526898A (ja) 2007-09-20
WO2005014623A2 (en) 2005-02-17
EP1660539B1 (en) 2010-06-02
EP1660539A2 (en) 2006-05-31
IL173532A0 (en) 2006-07-05
DE602004027508D1 (de) 2010-07-15
US20090105149A1 (en) 2009-04-23
ATE469921T1 (de) 2010-06-15
WO2005014623A3 (en) 2005-09-09
AU2004263203A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
BRPI0413373A (pt) compostos compreendendo lpa
DE60311820D1 (de) Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
ATE384526T1 (de) N-(((((1,3-thiazol-2- yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes
ATE386030T1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
BRPI0415288A (pt) composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
DK1781697T3 (da) Nyt carbamyleret erythropoietinprotein samt fremstillingsmetode
NO20061026L (no) Nye insulinderivater
NO20071369L (no) Antimikrobiske peptider omfattende et arginin- og/eller lysin-inneholdende motiv
EP2039699A3 (en) Extractive methods for purifying sucralose
CL2003001743A1 (es) Compuestos derivados de leucinamida, inhibidores de la cisteina proteasa; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la osteoporosis, enfermedad de paget's, peridontal, perdida
WO2004024757A3 (en) Modified pna molecules
WO2007125210A3 (fr) Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer ou de l'inflammation
ATE491463T1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
DK1561754T3 (da) Fremgangsmåde til fremstilling af 1,2-diaminocyclohexanplatin(II)-komplekser
ATE545655T1 (de) Fgfr-bindende peptide
EA200701852A1 (ru) Производные аминокислот
DE50300920D1 (de) Ferrocenylliganden und ein verfahren zur herstellung solcher liganden
EA200700425A1 (ru) Гликопротеин клеточной поверхности
WO2007045243A3 (en) Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
ATE505193T1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
WO2008022645A3 (en) Ncam fibronectin type 3 binding peptides

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.